---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455506"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-11-10T21:18:54+00:00"
generated_at: "2026-11-10T21:20:14.630045+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BBOT Q3 net loss $34.2M; BBO-8520 combo ORR 75% at 500mg in G12C-experienced NSCLC

## Summary
- Cash, cash equivalents and marketable securities totaled $315.3M at Sept 30, 2026, expected to fund operations into 2029.
- Q3 net loss $34.2M vs $44.8M a year ago; R&D $29.6M (vs $35.1M) and G&A $7.9M (vs $14.1M, which included a $7.8M BridgeBio Pharma stock charge).
- BBO-8520 plus pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC: 75% ORR at 500mg QD, 53% across dose levels (N=17); AEs mainly GI, favorable liver profile.
- BBO-8520 monotherapy in G12C inhibitor-naive NSCLC: 63% ORR (26/41), 100% DCR (41/41); 21 of 28 eligible patients remained on treatment beyond six months.
- BBO-11818 plus BBO-10203 and cetuximab combination dosing started in KRAS-mutant CRC and PDAC; monotherapy data updates for both expected in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-455506
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-11-10T21:18:54+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/0001193125-26-455506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/bbot-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455506
- JSON: https://secwatch.observer/filing/0001193125-26-455506.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.